Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24473448 | 0.96 | NTSR2 (0.53) | F2NTSR2NTSR1NPY1RNPY2R | |
| SCHEMBL24473407 | 0.92 | NPY4R (0.46) | F2NTSR2NTSR1NPY1RNPY2R | |
| SCHEMBL24473366 | 0.89 | NPY1R (0.48) | ACEMMECPA1ACE2NPY1R | |
| SCHEMBL24473409 | 0.89 | NPY1R (0.48) | NPY1RNPY2RNPY4RGHSRCHRND | |
| SCHEMBL24473375 | 0.88 | NPY1R (0.51) | F2ACEMMENPY1RNPY2R | |
| SCHEMBL24473513 | 0.87 | NPY4R (0.56) | NTSR2NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL24473479 | 0.87 | NPY4R (0.56) | NTSR2NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL24473382 | 0.87 | NPY4R (0.56) | NTSR2NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL24473300 | 0.87 | NPY4R (0.56) | NTSR2NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL24473470 | 0.87 | NPY4R (0.56) | NTSR2NTSR1NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | F2 1206/4885NTSR2 2/4885NTSR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.